114 studies found for:    "CINJ" OR "Cancer Intitute of New Jersey" | Open Studies | United States, New Jersey
Show Display Options
Rank Status Study
41 Recruiting Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma
Conditions: Leukemia;   Lymphoma
Intervention: Other: biologic sample preservation procedure
Study Type: Observational
Phase:
Funder Type: Other / NIH
Study Design: Observational Model: Case-Only;   Time Perspective: Prospective
Number Enrolled: 1000
Gender: Both
Age Groups: Child / Adult
NCT Number: NCT00897325
42 Recruiting Diet in Altering Disease Progression in Patients With Prostate Cancer on Active Surveillance
Condition: Prostate Cancer
Interventions: Behavioral: telephone-based intervention;   Other: counseling intervention;   Other: educational intervention;   Procedure: therapeutic dietary intervention
Study Type: Interventional
Phase:
Funder Type: Other / NIH
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 464
Gender: Male
Age Groups: Adult / Senior
NCT Number: NCT01238172
43 Recruiting Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer
Condition: Breast Cancer
Interventions: Procedure: therapeutic conventional surgery;   Radiation: whole breast irradiation
Study Type: Interventional
Phase: Phase 2
Funder Type: Other / NIH
Study Design: Intervention Model: Single Group Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 230
Gender: Female
Age Groups: Adult / Senior
NCT Number: NCT01556243
44 Unknown  Second Curettage in Treating Patients With Persistent Non-Metastatic Gestational Trophoblastic Tumor
Condition: Gestational Trophoblastic Tumor
Interventions: Other: laboratory biomarker analysis;   Procedure: conventional surgery
Study Type: Interventional
Phase: Phase 2
Funder Type: Other / NIH
Study Design: Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 66
Gender: Female
Age Groups: Child / Adult / Senior
NCT Number: NCT00521118
45 Recruiting Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: bicalutamide;   Drug: buserelin;   Drug: flutamide;   Drug: goserelin acetate;   Drug: leuprolide acetate;   Drug: triptorelin;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
Study Type: Interventional
Phase: Phase 3
Funder Type: Other / NIH
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 1520
Gender: Male
Age Groups: Adult / Senior
NCT Number: NCT00936390
46 Recruiting Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2)
Condition: Advanced, Metastatic Breast Cancer
Interventions: Drug: LEE011;   Drug: Letrozole;   Drug: LEE011 Placebo
Study Type: Interventional
Phase: Phase 3
Funder Type: Industry
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Double Blind (Subject,  Caregiver,  Investigator,  Outcomes Assessor)
Number Enrolled: 650
Gender: Female
Age Groups: Child / Adult / Senior
NCT Number: NCT01958021
47 Recruiting Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
Conditions: Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia
Interventions: Drug: Bendamustine Hydrochloride;   Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Biological: Rituximab
Study Type: Interventional
Phase: Phase 3
Funder Type: NIH
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Crossover Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 523
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT01886872
48 Recruiting Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Mucinous Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Malignant Ovarian Brenner Tumor;   Malignant Ovarian Mixed Epithelial Tumor;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Adenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Transitional Cell Carcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Cancer;   Stage III Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer;   Undifferentiated Fallopian Tube Carcinoma;   Undifferentiated Ovarian Carcinoma
Interventions: Behavioral: Behavioral Dietary Intervention;   Behavioral: Compliance Monitoring;   Other: Counseling;   Other: Educational Intervention;   Behavioral: Exercise Intervention;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
Study Type: Interventional
Phase: Phase 3
Funder Type: Other / NIH
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Primary Purpose: Prevention;   Masking: Open Label
Number Enrolled: 1070
Gender: Female
Age Groups: Adult / Senior
NCT Number: NCT00719303
49 Recruiting Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer
Conditions: Cervical Adenocarcinoma;   Cervical Adenosquamous Carcinoma;   Cervical Squamous Cell Carcinoma;   Chemotherapeutic Agent Toxicity;   Cognitive Side Effects of Cancer Therapy;   Psychological Impact of Cancer;   Radiation Toxicity;   Sexual Dysfunction and Infertility;   Stage IB Cervical Cancer;   Stage IIA Cervical Cancer;   Stage IIB Cervical Cancer;   Stage III Cervical Cancer;   Stage IVA Cervical Cancer
Interventions: Drug: Carboplatin;   Drug: Cisplatin;   Radiation: External Beam Radiation Therapy;   Radiation: Internal Radiation Therapy;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment
Study Type: Interventional
Phase: Phase 3
Funder Type: Other / NIH
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 780
Gender: Female
Age Groups: Adult / Senior
NCT Number: NCT01414608
50 Recruiting Phase III Study of DCVAC Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer
Condition: Metastatic Castrate Resistant Prostate Cancer
Interventions: Biological: Dendritic Cells DCVAC;   Biological: Placebo;   Drug: Docetaxel;   Drug: Taxotere
Study Type: Interventional
Phase: Phase 3
Funder Type: Industry
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Double Blind (Subject,  Caregiver,  Investigator)
Number Enrolled: 1170
Gender: Male
Age Groups: Adult / Senior
NCT Number: NCT02111577
51 Recruiting Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
Condition: Kidney Cancer
Interventions: Drug: gemcitabine hydrochloride;   Drug: sunitinib malate
Study Type: Interventional
Phase: Phase 2
Funder Type: Other / NIH
Study Design: Allocation: Randomized;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 100
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT01164228
52 Recruiting Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer
Condition: Lung Cancer
Interventions: Procedure: therapeutic thoracoscopy;   Procedure: videothoracoscopy
Study Type: Interventional
Phase: Phase 3
Funder Type: Other / NIH
Study Design: Allocation: Randomized;   Primary Purpose: Treatment
Number Enrolled: 1258
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT00499330
53 Unknown  Pentostatin, Cyclophosphamide, and Rituximab Followed By Lenalidomide in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia
Condition: Leukemia
Interventions: Biological: filgrastim;   Biological: pegfilgrastim;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: lenalidomide;   Drug: pentostatin
Study Type: Interventional
Phase: Phase 2
Funder Type: Other / NIH
Study Design: Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 110
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT00074282
54 Recruiting Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
Conditions: Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Non-Small Cell Lung Cancer
Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Crizotinib;   Drug: Erlotinib Hydrochloride;   Drug: Etoposide;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
Study Type: Interventional
Phase: Phase 2
Funder Type: NIH
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 234
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT01822496
55 Recruiting Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
Conditions: Recurrent Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Recombinant Interferon Alfa-2b
Study Type: Interventional
Phase: Phase 2
Funder Type: NIH
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 88
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT01708941
56 Not yet recruiting PARP Inhibitor BMN-673, Carboplatin, and Paclitaxel in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Condition: Adult Solid Neoplasm
Interventions: Drug: Carboplatin;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Pharmacological Study;   Drug: Talazoparib
Study Type: Interventional
Phase: Phase 1
Funder Type: NIH
Study Design: Allocation: Non-Randomized;   Endpoint Classification: Safety Study;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 72
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT02317874
57 Recruiting Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma
Conditions: Adult Solid Neoplasm;   Recurrent Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Riluzole;   Drug: Sorafenib Tosylate
Study Type: Interventional
Phase: Phase 1
Funder Type: NIH
Study Design: Endpoint Classification: Safety Study;   Intervention Model: Single Group Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 36
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT01303341
58 Recruiting A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting
Condition: HER2+ Metastatic Breast Cancer (MBC)
Interventions: Drug: neratinib;   Drug: capecitabine;   Drug: lapatinib
Study Type: Interventional
Phase: Phase 3
Funder Type: Industry
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 600
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT01808573
59 Recruiting LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)
Condition: Tumors With CDK4/6 Pathway Activation
Intervention: Drug: LEE011
Study Type: Interventional
Phase: Phase 2
Funder Type: Industry
Study Design: Allocation: Non-Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Single Group Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 90
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT02187783
60 Recruiting Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Condition: Carcinoma, Squamous Cell of Head and Neck
Interventions: Drug: VTX-2337;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: 5-fluorouracil;   Drug: Placebo
Study Type: Interventional
Phase: Phase 2
Funder Type: Industry
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Double Blind (Subject,  Caregiver,  Investigator,  Outcomes Assessor)
Number Enrolled: 175
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT01836029

First Page    Show previous page of results Previous Page (21-40) Studies Shown (41-60) Next Page (61-80) Show next page of results    Last Page
Indicates status has not been verified in more than two years